Abstract
The authors retrospectively explored the behavioral and functional imaging profile of Alzheimer's disease (AD) patients who respond to cholinesterase inhibitor therapy by using the Neuropsychiatric Inventory (NPI) and baseline [99mTc]HMPAO SPECT. Thirty AD patients were divided into three groups (Responders, Nonresponders, and Unchanged) based on their behavioral response to donepezil. Responders had significantly (P < or = 0.01) more pretreatment irritability, disinhibition (P < or = 0.05), and euphoria (P = 0.05) than Nonresponders and significantly lower lateral orbital frontal (P < 0.00001) and dorsolateral frontal (P < or = 0.0005) perfusion bilaterally. A pretreatment orbitofrontal syndrome may predict behavioral response to cholinesterase inhibitor therapy in AD.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Aged
-
Alzheimer Disease / diagnostic imaging
-
Alzheimer Disease / drug therapy*
-
Alzheimer Disease / physiopathology*
-
Behavior / drug effects
-
Behavior / physiology
-
Cerebrovascular Circulation / drug effects
-
Cerebrovascular Circulation / physiology*
-
Cholinesterase Inhibitors / therapeutic use*
-
Double-Blind Method
-
Female
-
Frontal Lobe / blood supply*
-
Frontal Lobe / diagnostic imaging
-
Humans
-
Image Processing, Computer-Assisted
-
Male
-
Psychiatric Status Rating Scales
-
Radionuclide Imaging
-
Radiopharmaceuticals
-
Technetium Tc 99m Exametazime
-
Trichlorfon / therapeutic use
Substances
-
Cholinesterase Inhibitors
-
Radiopharmaceuticals
-
Technetium Tc 99m Exametazime
-
Trichlorfon